Disclosures. Goals/Format. Patient 1 12/8/18. Antiretroviral Therapy Management. Harry Lampiris: None. Gabriel Chamie: None.
|
|
- Sheryl Summers
- 5 years ago
- Views:
Transcription
1 Disclosures Antiretroviral Therapy Management Panel Discussion & Debate Medical Management of AIDS & Hepatitis December 6, 2018 Harry Lampiris, MD, 1 Gabriel Chamie, MD, MPH 2 Susa Coffey, MD, 2 and Vivek Jain, MD, MAS 2 1 SFVAHCS, Infectious Disease Section, UCSF 2 Division of HIV, Infectious Diseases & Global Medicine, SF General Hospital, UCSF Harry Lampiris: None Gabriel Chamie: None Susa Coffey: None Vivek Jain: None Goals/Format Explore three cases highlighting modern topics in ART management Elicit audience opinions Patient 1 Expert panel reflections
2 Patient 1 32 yo HIV+ cisgender woman, recently diagnosed with HIV and referred for ART. She has no significant medical history and is on no medications. She wants to have children in the near-ish future. She would like to start ART, and prefers to take one pill per day. Audience Preliminary Vote Would you start bictegravir/taf/ftc (Biktarvy) in this patient? (A) Yes (B) No Case 1 Yes Case 1: Susa Yes, okay to initiate BIC/TAF/FTC ART should be started today -- our first priority is control of her HIV BIC/TAF/FTC is potent and tolerable, appropriate for RAPID ART start Noninferior to DTG + TAF/FTC; recommended in DHHS GL for 1 st line ART Data in women: naïve (limited) and switch studies Okay to offer BIC/TAF/FTC She is not pregnant now, and not desiring pregnancy immediately Can use contraception for the near term; could consider changing the regimen if/when she plans pregnancy Kityo, CROI 2018 Abs 500
3 What if? Case 1 Yes Safety of INSTIs in pregnancy: no evidence of a class effect BIC 25 pregnancies w/ BIC exposure, 18 prospectively reported + preconception or 1 st trimester exposure, no NTDs EVG/cobi 630 pregnancies, 155 prospectively reported and with preconception or 1 st trimester exposure. 2 reports of NTD, both retrospective reports. RAL Hundreds of pregnancies with 1 st trimester exposure, no e/o incr. risk of teratogenicity; the recommended INSTI in pregnancy (Perinatal GL) -Farrow T et al, Glasgow 2018, P030 -Perinatal GL -Antiretroviral Pregnancy Registry Case 1 Yes If not BIC, then what? (no perfect SPC options ) DTG/ABC/3TC need HLA B5701 result NNRTIs risk of transmitted resistance. Also: RPV/TFV/FTC need to know HIV VL, CD4 EFV/TDF/FTC really? AEs * DOR/TDF/FTC no data, no experience EVG/cobi/TFV/FTC: not recommended in pregnancy (Perinatal GL) * DRV/cobi/TAF/FTC DRV/cobi not recommended in pregnancy (Perinatal GL and package label) - low drug levels * (TAF: no data in pregnancy) * = problematic drug interactions with hormonal contraceptives If either of these is chosen now, must change in pregnancy Case 1 Yes Pt self efficacy she is capable of deciding what is best for her, after discussion of potential risks, benefits, and (significant) unknowns Case 1: Counterpoint: Gabe No, not comfortable initiating BIC/TAF/FTC DHHS: For those who are using effective contraception, a DTG-based regimen can be considered after weighing the risks and benefits of DTG use with the individual
4 Why to avoid BIC in this case 1. The main concern here is re: neural tube defects (NTD) /teratogenicity of future pregnancies for this 31 yo woman of child-bearing age with a desire to conceive in near future. Bictegravir is similar in chemical structure to Dolutegravir In Tsepamo study, the largest study to date of pregnancy outcomes among women on Dolutegravir, both pre-and post-conception, the risk of NTD was significantly increased compared with other ARVs Women on DTG at conception with NTD prevalence ~10x higher than all other scenarios Why to avoid BIC in this case 2. We do not have sufficient data on TAF in pregnancy TAF not approved in pregnant women 3. Not ideal to start a regimen and change shortly thereafter. We have other effective (though not SPC) options: DRV/r + Truvada or ATV + Truvada if she is not planning to use contraception and planning to conceive RPV/TDF/FTC once VL & GT back 4. Worth noting that major studies of Bictegravir in ART-naïve patients (GS-1489 & 1490) ~90% of participants were men 5. Why take the risk in this young woman who wishes to conceive at this point when there are other safer options? Zash, IAS, 2018 Final Audience Vote Would you start bictegravir/taf/ftc (Biktarvy) in this patient? (A) Yes (B) No Case 1 Consensus 1. Overall, Tsepamo data finding an association with DTG use and NTD represent a concerning, preliminary signal, and without further data on BIC (or TAF) in conception/pregnancy, cannot recommend use of bictegravir in this patient planning to conceive 2. However, important to discuss risks/benefits for well-informed, patient-centered decision-making. May proceed if patient understands and willing to accept the risk; also ok if on effective contraception 3. No evidence of increased risk of starting DTG during pregnancy, and INSTIs remain important tool for rapid viral suppression particularly women initiating ART late in pregnancy For more: Dr. Cohan, Reproductive Health, Friday 1:20PM
5 Patient 2 Patient 2 26 year old man with active substance use diagnosed with HIV. WT genotype at ART start. Prescribed TAF/FTC and DTG initially. Says pharmacy dispensed only TAF/FTC last month. He thought his provider must have discontinued DTG), and he has been off DTG for a few weeks. His VL is 2,500 and there is a new M184V on repeat GT. He really would like a single pill combination, and admits he struggles with daily adherence. Debate topic: Is BIC/TAF/FTC an acceptable regimen in this case? Audience Preliminary Vote Would you (A) Prescribe BIC/TAF/FTC (B) Prescribe DRV/c/TAF/FTC Case 2: Gabriel Chamie Yes, ok to use BIC/FTC/TAF in this patient
6 Case 2: Yes use BIC/FTC/TAF We now have prospective data supporting use of EVG/c/FTC/TAF in pts with M184v or M184I Open-label, single arm switch study to E/C/F/TAF in suppressed patients with historical GT with M184V/I, no INSTI or PI-resistance, no additional NRTI or PI mutations on sequencing of integrated DNA, no history of virologic failure, and on stable ART regimen -> VS at 24 wks Abstract TUAB0104-Table 1. No virological failures or emergent resistance PerezValero, IAS, 2018, Abstract TUAB0104 Case 2: Yes use BIC/FTC/TAF We also have retrospective observational data that switch to DTG and EVG/c single tablet regimens in pts with M184V maintains high levels viral suppression (VS) 51 patients with VS and prior genotyping switched to DTG/ABC/3TC or EVG/c/TDF/FTC 47 with RNA GT, and 4 with DNA GT only M184V most common (present in 88% of GTs) After median 13 months follow-up, only 1 case of VF (failed >2 years after switch, and had poor adherence) Pronier, IAS, 2017, Abstract MOPEB0320 Case 2: Yes use BIC/FTC/TAF Bictegravir Similar chemical structure to Dolutegravir In vitro has resistance profile similar to Dolutegravir, and also has a higher barrier to drug resistance than RAL or EVG/c Well-tolerated SPC may be optimal, if poor adherence in this patient is due to intolerance or trouble managing >1 pill Case 2: Counterpoint: Harry Lampiris No, I would not use Biktarvy in a patient with a history of virologic failure and an M184V mutation Chemical structure of bictegravir Markham, Drugs, 2018
7 Case 2: Counterpoint What are the potential choices for a simple regimen in a patient with prior M184V? The strongest data supports a boosted-pi based regimen, such as SYMTUZA An alternative potent regimen would be DOL + TAF/FTC but this is not an STR BIKTARVY (no reported experience), but might be willing to use at some point in the future TRIUMEQ ( or any ABC/3TC based regimen) not appealing because M184V makes abacavir less active, therefore neither NRTI protects INSTI What about GENVOYA? Study 1824: Suppressed Adults with M184V/I Switched to E/C/F/TAF Part 1 Part 2 Study Design Ongoing, multicenter, international, open label, single arm study in HIV-1-infected adults with HIV-1 RNA < 50 copies/ml receiving FTC/TDF or ABC/3TC + third agent NRTI-R: M184V/I only NRTI-R: M184V/I and up to 2 TAMs* N = 37 N = 50 enrolling *TAMs: M41L, D67N, K70R, L210W, T215Y/F, and K219Q/E/N/R E/C/F/TAF QD 12 weeks 24 weeks E/C/F/TAF QD 12 weeks 24 weeks Primary Endpoint HIV-1 RNA < 50 copies/ml at Week 12 using PVR (pure virologic response) *Pure Virologic Response defined with no confirmed virologic failure before W12 or W24, absence of premature discontinuation with last VL 50 c/ml. DC prior to W12 or W24 for other than viral rebound are considered to have PVR. 1. Perez-Valero I, et al. IDRW 2017; 2. Perez-Valero I, et al. AIDS Amsterdam, NL. Amsterdam. Netherlands. Oral TUAB weeks 48 weeks Baseline Resistance (n=37) Efficacy and Safety Results through Week 24 Study 1824: Suppressed Adults with M184V/I Switched to E/C/F/TAF (Part 1 interim analysis) Historical Proviral DNA* M184V/I only n=18 M184V/I +NNRTI-R n=19 WT n=19 M184V/I only n=8 Historical genotype: All participants had M184V/I Approximately half of participants also had NNRTI-R HIV-1 *Genosure Archive Perez-Valero I, et al. AIDS Amsterdam, NL. Poster TUAB0104 M184V/I +NNRTI-R n=8 NNRTI-R only n=2 Study 1824: Suppressed Adults with M184V/I Switched to E/C/F/TAF (Part 1 interim analysis) Participants, % Efficacy Analysis by PVR* 100% W12 100% N=37/37 W24 HIV RNA < 50 copies/ml Switching to E/C/F/TAF may be an option for virologically suppressed participants with pre-existing M184V and/or M184I mutations *Pure virologic response defined with no confirmed virologic failure before W12 or W24, absence of premature discontinuation with last VL 50 c/ml. DC prior to W12 or W24 for other than viral rebound are considered to have PVR. **Muscle spams Perez-Valero I, et al. AIDS Amsterdam, NL. Poster TUAB0104 0% W12 0% W24 (37/37) (37/37) (0/37) (0/37) HIV RNA 50 copies/ml Study Drug-Related Adverse Events (AEs) E/C/F/TAF (n=37) n (%) Any Study Drug-Related AE 8 (22) Any Grade 3 or 4 Study Drug-Related AE 0 (0) AEs Leading to Premature Study Drug Discontinuation ** 1 (3)
8 Final Audience Vote Would you (A) Prescribe BIC/TAF/FTC Patient 3 (B) Prescribe DRV/c/TAF/FTC Patient 3 Patient 3 (con t) 67 yo man with AIDS, CD4 nadir 30, HIV positive since 1988 Active problems include osteoporosis, depression, insomnia, HBsAg positive with suppressed HBV DNA Currently has hyperlipidemia which is not well controlled with high dose rosuvastatin Has a long history of intermittent ARV adherence Is it possible to change his ARV regimen to better manage his hyperlipidemia? ARV history: D4T, 3TC, DDI, ABC, TDF, NVP, NLF, lopinavir/r, in the past, with intermittent viremia Current meds: DRV/c + TAF/FTC, rosuvastatin, omeprazole, Ca/VitD, trazodone, mirtazapine Recent labs: CD4 267, HIV RNA <40 detected, Cr 1.5, chol 250, TG 273, HDL 40, LDL 183, LFTs WNL Prior genotype: RT M41L, L74V, K103N, Y181C, M184V, T215F PI L10I, K20R, M36I, M46I, I54V, L63P, G73S, V82A, L90M
9 Audience Preliminary Vote Would you change this patient s regimen to bictegravir/taf/ftc + doravirine? A. Yes Case 3: Harry Yes, change to BIC/TAF/FTC + DOR B. No Case 3: Why to change to BIK + DOR Simple regimen for this patient which is PIsparing Lipid improvements with changing off DRV/c based regimens have been demonstrated in multiple studies DOR has been studied in switch studies in suppressed patients (DRIVE SHIFT) Doravirine has high genetic barrier, no food requirements, minimal DDIs, no HL, minimal neuropsychiatric side effects or rash Case 3: Counterpoint: Susa No, do not change to BIC/TAF/DOR
10 No, don t change to BIK + DOR This regimen is working well continue it to maintain virologic control (can simplify to D/c/F/TAF for SPC) 3 arguments: 1) Data and clinical experience do not support use of DOR or BIC No clinical data on BIC with resistant virus, some in vitro data No clinical data on DOR with resistant virus In vitro data DRIVE-SHIFT in stable suppressed pts, no resistance to components DOR: unclear barrier to resistance VF in naïve studies-> emergence of multiple NNRTI mutations 2 NNRTI mutations present (K103N, Y181C), and multip NRTIs muts (impaired NRTI backbone) In vitro data suggest modest incr in DOR IC50, but NOT studied in people! What if NNRTI mutations not seen on GT? No, don t change to BIC + DOR 2) Pt has long history of intermittent ARV adherence Consequence of VF here may be huge new RT + IN resistance 3) D/c of PI won t be enough to lower lipids LDL = 183 mg/dl on statin DRIVE-FORWARD - DOR vs DRV/r: mean diff in LDL = 14 mg/dl at wk 48, 19 for TC DRIVE-SHIFT: group changed DOR/TDF/FTC from rtv-boosted PI: mean decr LDL = 16.5 mg/dl at week 24, 26 for TC Switch to BIC from PI/b (DRV or ATV): mean decr LDL 2-7 at wk 48 Optimize control of lipids eg, add ezetimibe, PSK9 inhib. No, don t change to BIC + DOR Proposed change is too risky -- and w/o more data and additional compelling reason to change the ART, would not do Can reevaluate when we have more data on or clinical experience with BIC and DOR Final Audience Vote Would you change this patient s regimen to bictegravir/taf/ftc + doravirine? A. Yes B. No
11 Bonus Case 45y.o. man newly diagnosed with HIV: CD4=438, VL=81,000, and genotype=wild type. Initiates therapy with Triumeq. Within first 2 weeks, complains of headache. You counsel him to continue Triumeq while you monitor At approximately 8 weeks of therapy, the headache is persistent and he wishes to switch to another drug as it is affecting his work. What do you recommend switching to? Audience Vote (A) Symtuza (TAF/FTC/cobi/DRV) (B) Biktarvy (TAF/FTC/BIC) (C) Odefsey (TAF/FTC/RPV) (D) ABC/3TC + RAL Panelist Commentary (A) Symtuza (TAF/FTC/cobi/DRV) (B) Biktarvy (TAF/FTC/BIC) (C) Odefsey (TAF/FTC/RPV) (D) ABC/3TC + RAL Acknowledgements Monica Gandhi, MD Oliver Bacon, MD Annie Luetkemeyer, MD Thank you for participating!
Switching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches
Switching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches Harry W. Lampiris, MD Chief, Infectious Disease Section, San Francisco VA Medical Center Professor
More informationRESEARCH B/F/TAF in Treatment-Naïve HIV-1 and HIV-1 RNA Suppressed Switch Patients
RESEARCH B/F/TAF in Treatment-Naïve HIV-1 and HIV-1 RNA Suppressed Switch Patients Kirsten White Gilead Sciences, Inc., Foster City, CA Background Bictegravir (BIC; B) is a novel, unboosted integrase strand
More informationDisclosures. Introduction to ARV Drug Resistance New Clinicians Workshop. Introduction. ARS Question
Disclosures Introduction to ARV Drug Resistance New Clinicians Workshop I have no disclosures Susa Coffey, MD Division of HIV, ID and Global Medicine ARS Question Which resistance test do you order for
More informationDisclosures. Introduction to ARV Drug Resistance New Clinicians Workshop 12/9/16. Introduction. ARS Question
Disclosures Introduction to ARV Drug Resistance New Clinicians Workshop I have no disclosures Susa Coffey, MD Division of HIV, ID and Global Medicine ARS Question Which resistance test do you order for
More informationDisclosures. Introduction to ARV Drug Resistance New Clinicians Workshop. Introduction. ARS Question 12/6/2017
Disclosures Introduction to ARV Drug Resistance New Clinicians Workshop I have no disclosures Susa Coffey, MD Division of HIV, ID and Global Medicine ARS Question Which resistance test do you order for
More informationPanelists Melanie Thompson Jeffrey Lennox Wendy Armstrong Jonathan Li
Slide 1 of 51 Interactive ART Cases From the Clinic(ians): Case-Based Panel Discussion Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University
More informationHIV 101. Applications of Antiretroviral Therapy
HIV 101. Applications of Antiretroviral Therapy Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University of Alabama at Birmingham Birmingham,
More informationAntiretroviral Therapy: Panel Discussion
disclosures Antiretroviral Therapy: Panel Discussion Medical Management of HIV December 9, 217 Panelists: Harry Lampiris, MD; Annie Luetkemeyer, MD; Carina Marquez, MD Moderator: Oliver Bacon, MD none
More informationAntiretroviral Treatment Strategies: Clinical Case Presentation
Antiretroviral Treatment Strategies: Clinical Case Presentation Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan Chia-Jui, Yang M.D Disclosure No conflicts of interests.
More informationReport Back: HIV Treatment Updates
Report Back: HIV Treatment Updates Catherine Koss, MD Assistant Professor Division of HIV, Infectious Diseases, and Global Medicine Zuckerberg San Francisco General Hospital University of California, San
More information11/7/2016. Antiretroviral Therapy Strategies. Learning Objectives. After attending this presentation, participants will be able to:
Antiretroviral Therapy Strategies FORMATTED: 1/14/16 Joel E. Gallant, MD, MPH Medical Director of Specialty Services Southwest CARE Center Santa Fe, New Mexico Adjunct Professor of Medicine The Johns Hopkins
More informationResistance Workshop. 3rd European HIV Drug
3rd European HIV Drug Resistance Workshop March 30-April 1 st, 2005 Christine Hughes, PharmD Clinical Associate Professor Faculty of Pharmacy & Pharmaceutical Sciences University of Alberta Tenofovir resistance
More informationHIV Clinical Management: Antiretroviral Therapy and Drug Resistance
HIV Clinical Management: Antiretroviral Therapy and Drug Resistance Judith S. Currier, MD, MSc Professor of Medicine University of California, Los Angeles Disclosures: Research Grant from Theratechnologies
More informationCases from the Clinic(ians): Case-Based Panel Discussion
Cases from the Clinic(ians): Case-Based Panel Discussion Michael S. Saag, MD Professor of Medicine The University of Alabama at Birmingham EDITED: 03-12-14 Learning Objectives After attending this presentation,
More informationDisclosures. Patient 1. Goals/Format 12/7/17. Antiretroviral Therapy Management:
Disclosures Antiretroviral Therapy Management: Panel Discussion & Debate Medical Management of AIDS & Hepatitis December 8, 2017 Brad Hare, MD, 1 Annie Luetkemeyer, MD 2 Susa Coffey, MD, 2 Vivek Jain,
More informationSelecting an Initial Antiretroviral Therapy (ART) Regimen
Selecting an Initial Antiretroviral Therapy (ART) Regimen An HIV Diagnosis is a Call to Action In support of the NYSDOH AIDS Institute s January 2018 call to action for patients newly diagnosed with HIV,
More informationClinical support for reduced drug regimens. David A Cooper The University of New South Wales Sydney, Australia
Clinical support for reduced drug regimens David A Cooper The University of New South Wales Sydney, Australia Clinical support for reduced drug regimens First line optimisation Virological failure New
More informationThe next generation of ART regimens
The next generation of ART regimens By Gary Maartens Presented by Dirk Hagemeister Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Current state
More informationGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
More informationCase # 1. Case #1 (cont d)
Antiretroviral Therapy Management: Expert Panel Discussion George Beatty Susa Coffey Steve O Brien December 3, 2011 Moderated by Annie Luetkemeyer Case # 1 38 y.o. man, CD4 =350, VL=340K, new to your clinic
More informationDidactic Series. CROI 2014 Update. March 27, 2014
Didactic Series CROI 2014 Update Christian Ramers, MD, MPH Family Health Centers of San Diego Ciaccio Memorial Clinic Jacqueline Peterson Tulsky, MD UCSF Positive Health Program at SFGH Medical Director,
More informationSimplifying HIV Treatment Now and in the Future
Simplifying HIV Treatment Now and in the Future David M. Hachey, Pharm.D., AAHIVP Professor Idaho State University Department of Family Medicine Nothing Disclosure 1 Objectives List current first line
More informationComprehensive Guideline Summary
Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents AETC NRC Slide Set Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and
More informationMore Options, Some Opinions Initial Therapies for HIV Judith S. Currier, MD
More Options, Some Opinions Initial Therapies for HIV Judith S. Currier, MD More Options, Some Opinions: Initial Therapies for HIV Judith S. Currier, MD University of California Los Angeles Los Angeles,
More informationManagement of patients with antiretroviral treatment failure: guidelines comparison
The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral
More informationCROI 2018 Report Back
CROI 2018 Report Back Monika Roy, MD MAS Assistant Professor Division of HIV, Infectious Diseases, and Global Medicine bayareaaetc.org 1 Disclosures and Conflicts of Interest Nothing to report bayareaaetc.org
More informationThird Agent Advantages Disadvantages. Component Tenofovir/emtricitabine (TDF/FTC) 300/200 mg (coformulated with EFV as Atripla) 1 tab once daily
Table I. Recommended and Alternative Antiretroviral Regimens (DHHS Guidelines, May 1, 2014) Recommended Regimens Nucleoside Analog Reverse Transcriptase Inhibitor (NRTI) Third Agent Advantages Disadvantages
More informationHIV Treatment Update. Anton Pozniak Consultant Physician, Director of HIV Services Chelsea and Westminster Hospital, London
HIV Treatment Update Anton Pozniak Consultant Physician, Director of HIV Services Chelsea and Westminster Hospital, London Guidelines Nuke sparing Nukes Efavirenz placement as the gold standard ARV Role
More informationCROI 2017 Review: Novel ART Strategies
Mountain West AIDS Education and Training Center CROI 2017 Review: Novel ART Strategies Brian R. Wood, MD Assistant Professor of Medicine Medical Director, Mountain West AETC ECHO Telehealth March 2, 2017
More informationAre the current doses of ARV correct. Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine
Are the current doses of ARV correct Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine Can we lower doses of HIV meds safely? Consensus Panel in Alexandria
More informationManagement of NRTI Resistance
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Management of NRTI Resistance David Spach, MD Principal Investigator, NW AETC Professor of Medicine, Division of Infectious Diseases University of Washington
More informationAntiretroviral Therapy: What to Start
FLOWED: 05-14-2015 Chicago, IL: May 18, 2015 Antiretroviral Therapy: What to Start Eric S. Daar, MD Professor of Medicine David Geffen School of Medicine University of California Los Angeles Los Angeles,
More informationID Week 2016: HIV Update
Mountain West AIDS Education and Training Center ID Week 2016: HIV Update Robert Harrington, M.D. This presentation is intended for educational use only, and does not in any way constitute medical consultation
More information2016 Perinatal Treatment Guidelines Update
Mountain West AIDS Education and Training Center 2016 Perinatal Treatment Guidelines Update Shireesha Dhanireddy, MD Associate Professor of Medicine, University of Washington 2 November 2016 This presentation
More informationUpdates to the HHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV Updated October 17, 2017
Mountain West AIDS Education and Training Center Updates to the HHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV Updated October 17, 2017 26 October 2017 Hillary
More informationCase 1 continued. Case 1 (cont) 12/8/16. MMAH Debate Panel Thursday, December 8, Case 1
MMAH Debate Panel Thursday, December 8, 2016 Case 1 HPI 55 yo man with newly diagnosed HIV initiates care in your clinic. His CD4+ cell count is 600, with HIV VL=90,000 copies/ml. He is asymptomatic at
More informationAntiretroviral Therapy in 2016
Antiretroviral Therapy in 2016 Joel Gallant, MD, MPH Southwest CARE Center Santa Fe, NM University of New Mexico School of Medicine Johns Hopkins University School of Medicine Disclosures Consulting, Advisory
More informationHIV Treatment: New and Veteran Drugs Classes
HIV Treatment: New and Veteran Drugs Classes Jonathan M Schapiro, MD National Hemophilia Center Stanford University School of Medicine Rome, March 2013 Overview Many excellent antiretroviral agents are
More informationINTERGRASE INHIBITORS- WHAT S NEW?
INTERGRASE INHIBITORS- WHAT S NEW? Professor Margaret Johnson Royal Free London Foundation Trust October 2018 Targeting the HIV life-cycle NEW HIV VIRON MATURATION CO-RECEPTOR BINDING FUSION BUDDING CD4
More informationState of the ART: Integrase Inhibitors Clinical Data. Juan Berenguer Hospital General Universitario Gregorio Marañón (IiSGM) Madrid, Spain
State of the ART: Integrase Inhibitors Clinical Data Juan Berenguer Hospital General Universitario Gregorio Marañón (IiSGM) Madrid, Spain Disclosures Consulting fees and honoraria Gilead, Janssen, MSD,
More informationThe Integrase Inhibitor Drug Class: A Comparative Clinical Review
The Integrase Inhibitor Drug Class: A Comparative Clinical Review Ian Frank Professor of Medicine University of Pennsylvania Philadelphia, PA USA franki@pennmedicine.upenn.edu Disclosure Gilead, ViiV/GlaxoSmithKline:
More informationThe Use of Integrase Inhibitors In Latin America: From Guidelines to the Real World Ernesto Martínez B., MD Internal Medicine, Infectious Diseases
De afbeelding kan niet worden weergegeven. The Use of Integrase Inhibitors In Latin America: From Guidelines to the Real World Ernesto Martínez B., MD Internal Medicine, Infectious Diseases DISCLOSURE
More informationSTRIBILD (aka. The Quad Pill)
NORTHWEST AIDS EDUCATION AND TRAINING CENTER STRIBILD (aka. The Quad Pill) Brian R. Wood, MD Medical Director, NW AETC ECHO Assistant Professor of Medicine, University of Washington Presentation prepared
More informationVirological suppression and PIs. Diego Ripamonti Malattie Infettive - Bergamo
Virological suppression and PIs Diego Ripamonti Malattie Infettive - Bergamo Ritonavir-boosted PIs Boosted PIs: 3 drugs in one The intrinsic antiretroviral activity Viral suppression and high baseline
More informationARVs in Development: Where do they fit?
The picture can't be displayed. ARVs in Development: Where do they fit? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures The speaker
More informationPrima linea: dovremmo evitare i PI nella terapia di prima linea per i loro effetti non desiderati? Giuseppina Liuzzi
6 th INFECtivology TOday Paestum 15-16 -17 maggio 2014 Prima linea: dovremmo evitare i PI nella terapia di prima linea per i loro effetti non desiderati? Giuseppina Liuzzi Istituto Nazionale per le Malattie
More informationCROI 2017 Highlights What s New in Antiretrovirals (Part 2)
Mountain West AIDS Education and Training Center CROI 2017 Highlights What s New in Antiretrovirals (Part 2) Ann Collier, MD This presentation is intended for educational use only, and does not in any
More informationDidactic Series. Switching Regimens in the Setting of Virologic Suppression
Didactic Series Switching Regimens in the Setting of Virologic Suppression Craig Ballard, PharmD, AAHIVP UC San Diego Health Owen Clinic June 14 th, 2018 1 Learning Objectives 1) Describe DHHS guidelines
More informationTreating HIV: When the Guidelines Don t Fit. Joel Gallant, MD, MPH. Southwest CARE Center Santa Fe, New Mexico
Treating HIV: When the Guidelines Don t Fit Joel Gallant, MD, MPH Southwest CARE Center Santa Fe, New Mexico Johns Hopkins University School of Medicine University of New Mexico School of Medicine Disclosures
More informationWhat s New. In The 2016 Perinatal HIV Treatment Guidelines? Provided by CDC s Elimination of Perinatal HIV Transmission Stakeholders Group
What s New In The 2016 Perinatal HIV Treatment Guidelines? Provided by CDC s Elimination of Perinatal HIV Transmission Stakeholders Group Guidelines for our Online Meeting Room You will be listening to
More informationDNA Genotyping in HIV Infection
Frontier AIDS Education and Training Center DNA Genotyping in HIV Infection Steven C. Johnson M.D. Director, University of Colorado HIV/AIDS Clinical Program; Professor of Medicine, Division of Infectious
More informationTreating HIV in 2018 Interactive Cases From the Clinic(ians)
Slide 1 of 51 Treating HIV in 2018 Interactive Cases From the Clinic(ians) Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University of Alabama
More informationDr Marta Boffito Chelsea and Westminster Hospital, London
Dr Marta Boffito Chelsea and Westminster Hospital, London Speaker Name Statement Dr Marta Boffito has received travel and research grants from and has been an advisor for Janssen, Roche, Pfizer, ViiV,
More informationHistory (August 2010) Therapy for Experienced Patients. History (September 2010) History (November 2010) 12/2/11
(August 2010) Therapy for Experienced Patients Hiroyu Hatano, MD, MHS Assistant Professor of Medicine University of California San Francisco Medical Management of AIDS December 2011 42M HIV (CD4=450, VL=6250,
More informationSomnuek Sungkanuparph, M.D.
HIV Drug Resistance Somnuek Sungkanuparph, M.D. Associate Professor Division of Infectious Diseases Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University Adjunct Professor
More informationTwo Drug Regimens Pros and Cons. Jürgen Rockstroh Department of Medicine I University Hospital Bonn, Bonn, Germany
Two Drug Regimens Pros and Cons Jürgen Rockstroh Department of Medicine I University Hospital Bonn, Bonn, Germany HIV Clinical Forum, Moscow, Russia, Friday 23 rd November 2018 Conflict of Interest: JKR
More informationSwitching antiretroviral therapy to safer strategies based on integrase inhibitors
Switching antiretroviral therapy to safer strategies based on integrase inhibitors Dr Paddy Mallon UCD HIV Molecular Research Group UCD School of Medicine paddy.mallon@ucd.ie UCD School of Medicine & Medical
More informationDoes Resistance Still Matter? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School
Does Resistance Still Matter? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosure The speaker serves as a consultant to, and has received
More informationDRUGS IN PIPELINE. Pr JC YOMBI UCL-AIDS REFERENCE CENTRE BREACH Sept 27, 2015
DRUGS IN PIPELINE Pr JC YOMBI UCL-AIDS REFERENCE CENTRE BREACH Sept 27, 2015 N(t)RTI The Development of TAF TAF Delivers the High Potency of TDF While Minimizing Off- Target Kidney and Bone Side Effects
More informationDolutegravir: Pros and Cons (Are There Any Cons?)
Mountain West AIDS Education and Training Center Dolutegravir: Pros and Cons (Are There Any Cons?) Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical Director, MW AETC
More informationSwitching antiretroviral therapy to safer strategies based on integrase inhibitors. Pedro Cahn
Switching antiretroviral therapy to safer strategies based on integrase inhibitors Pedro Cahn Disclosures Research Grants: Abbvie-Merck-Richmond-ViiV Advisory boards: Merck-Sandoz-ViiV Switching in Virologically
More informationManagement of ART Failure. EACS Advanced HIV Course 2015 Dr Nicky Mackie
Management of ART Failure EACS Advanced HIV Course 2015 Dr Nicky Mackie Outline Defining treatment success Defining treatment failure Reasons for ART failure Management of ART failure Choice of second
More informationStarting Immediate Treatment for HIV-1
Starting Immediate Treatment for HIV-1 Ronald P. Hattis, MD, MPH Email: ronhattis@foundation.beyondaids.org Associate Prof. of Preventive Medicine, Loma Linda University Secretary, Beyond AIDS Foundation
More informationHIV Treatment in 2018: What s New & How To Communicate Those Messages
HIV Treatment in 2018: What s New & How To Communicate Those Messages Jeffrey Kwong, DNP, MPH, ANP BC, FAANP Carole Treston, RN, MPH, FAAN Diego Villalba, Pharm D USCA September 7, 2018 The Association
More informationDisclosures (last 12 months)
HIV Research What s in the Pipeline? Samir K. Gupta, MD, MS Division of Infectious Diseases Indiana University School of Medicine Disclosures (last 12 months) Independent research grant funding by NIH/NHLBI,
More informationHIV Treatment Update
HIV Treatment Update Joel Gallant, MD, MPH Southwest CARE Center Santa Fe, NM Johns Hopkins University School of Medicine University of New Mexico School of Medicine Disclosures Consulting, Advisory Boards,
More informationACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals
Initial Therapy for Antiretroviral Naïve HIV Infected Patients Michelle Cespedes, MD, MS Associate Professor of Medicine Division of Infectious Disease Icahn School of Medicine at Mount Sinai Disclosures
More informationDolutegravir-Rilpivirine (Juluca)
Dolutegravir-Rilpivirine (Juluca) David H. Spach, MD Clinical Director, MW AETC Professor of Medicine Division of Infectious Diseases University of Washington Last Updated: November 30, 2017 ANTIRETROVIRAL
More informationFirst line ART Rilpirivine A New NNRTI. Chris Jack Physician, Durdoc Centre ethekwini
First line ART Rilpirivine A New NNRTI Chris Jack Physician, Durdoc Centre ethekwini Overview: Rilpirivine an option for ARV Naïve patients History Current guidelines Efficacy and Safety Tolerability /
More informationAntiretroviral Treatment 2014
Activity Code FM285 Antiretroviral Treatment 2014 Rajesh Gandhi, MD Masssachusetts General Hospital Disclosures: Educational grants to my institution from Janssen, Viiv, Abbott Learning Objectives Upon
More informationState of the art of ART
No disclosures State of the art of ART Medical Management of AIDS December 7, 2017 Monica Gandhi MD, MPH Professor of Medicine, Division of HIV, Infectious Diseases and Global Medicine, UCSF Medical Director,
More informationDr Carole Wallis, PhD Medical Director, BARC-SA Head of the Specialty Molecular Division, Lancet Laboratories, South Africa
Dr Carole Wallis, PhD Medical Director, BARC-SA Head of the Specialty Molecular Division, Lancet Laboratories, South Africa Transmitted drug resistance Resistance patterns in first-line failures in adults
More informationIntroduction to HIV Drug Resistance. Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School
Introduction to HIV Drug Resistance Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School Objectives 1. Describe the epidemiology of HIV drug resistance in sub-saharan Africa. 2.
More informationHIV Update Allegra CPD Day Program Port Elizabeth Dr L E Nojoko
HIV Update 2014 Allegra CPD Day Program Port Elizabeth 12-02-2014 Dr L E Nojoko Global estimates for adults and children 2011 People living with HIV 34.0 million [31.4 million 35.9 million] New HIV infections
More informationSecond-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Second-Line Therapy David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases University of Washington Presentation
More informationPotential Issues in Treating HIV/HCV co-infection with new HCV antivirals
State of the Art in Hepatitis C Virus Infection in HIV/HCV-Coinfected Patients FORMATTED: 11/17/15 David L. Wyles, MD Associate Professor of Medicine University of California San Diego San Diego, California
More information2 nd Line Treatment and Resistance. Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012
2 nd Line Treatment and Resistance Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012 Overview Basics of Resistance Treatment failure Strategies to manage treatment failure Mutation Definition: A change
More informationSwitching strategies and ARV treatment costs
February 2014 Switching strategies and ARV treatment costs Josep M Llibre/Bonaventura Clotet Fundació Lluita contra la SIDA Hosp Univ Germans Trias i Pujol Badalona Rationale. Spain is under a huge economic
More informationResistance to Integrase Strand Transfer Inhibitors
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Resistance to Integrase Strand Transfer Inhibitors David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases
More informationCrafting an ART Regimen for Initiation or Salvage: Are NRTI s Necessary?
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Crafting an ART Regimen for Initiation or Salvage: Are NRTI s Necessary? Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical
More informationAntiretroviral Drugs
Antiretroviral Drugs Dr Paddy Mallon UCD HIV Molecular Research Group Associate Dean for Research and Innovation UCD School of Medicine and Medical Science paddy.mallon@ucd.ie UCD School of Medicine &
More informationDrug toxicities: Safest PIs. Michelle Moorhouse 14 Apr 2016
Drug toxicities: Safest PIs Michelle Moorhouse 14 Apr 2016 Impact of PIs on AIDS mortality CDC.gov. Epidemiology of HIV infection. Evolution of PIs http://www.clinicaloptions.com/hiv/treatment%20updates/boosted%20pis/interactive%20virtual%20presentation/slideset.aspx
More informationKees Brinkman OLVG- Amsterdam The Netherlands
integrase inhibitors in clinical practice in the Netherlands HIV Clinical Forum 2018 Kees Brinkman OLVG- Amsterdam The Netherlands Disclosures relevant activities to dislose companies advisory boards Gilead
More informationEviplera: New First-Line Treatment Options for patients with HIV (own clinical experience in Izrael) Itsik Levy MD
Eviplera: New First-Line Treatment Options for patients with HIV (own clinical experience in Izrael) Itsik Levy MD Population: 8,000,000 Ethnic groups: 75% Jewish 20% Arabs 5% Others HCS PPC 3.5/1000 NPC
More informationDavid Cluck, PharmD, BCPS, AAHIVP Associate Professor of Pharmacy Practice Office 326 Phone
David Cluck, PharmD, BCPS, AAHIVP Associate Professor of Pharmacy Practice Office 326 Phone 423-439-6245 Email cluckd@etsu.edu Recall newly approved antiretrovirals and their respective place in therapy
More information2nd line failure, provincial evaluation process for 3rd line therapy, 3rd line treatment options James Nuttall
2nd line failure, provincial evaluation process for 3rd line therapy, 3rd line treatment options James Nuttall Paediatric Infectious Diseases Unit, Red Cross War Memorial Children s Hospital & University
More informationManagement of Treatment-Experienced Patients: New Agents and Rescue Strategies. Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine
Management of Treatment-Experienced Patients: New Agents and Rescue Strategies Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine When to Modify Therapy! Studies to date show better responses
More informationBHIVA Best of CROI Feedback Meetings. London Birmingham North West England Cardiff Gateshead Edinburgh
BHIVA Best of CROI Feedback Meetings London Birmingham North West England Cardiff Gateshead Edinburgh BHIVA Best of CROI Feedback Meetings 2010 ANTIRETROVIRAL TREATMENT STRATEGIES AND NEW DRUGS A5202:
More informationHIV Treatment Update 8/3/2015. When to Start. Disclosures
8/3/215 HIV Treatment Update Joel Gallant, MD, MPH Southwest CARE Center Santa Fe, NM University of New Mexico School of Medicine Johns Hopkins University School of Medicine Disclosures Consulting, Advisory
More informationEfficacy and Safety of Doravirine 100mg QD vs Efavirenz 600mg QD with TDF/FTC in ART-Naive HIV-Infected Patients: Week 24 Results
Efficacy and Safety of Doravirine 1mg QD vs Efavirenz 6mg QD with TDF/FTC in ART-Naive HIV-Infected Patients: Week 24 Results Jose M. Gatell, Francois Raffi, Andreas Plettenberg, Don Smith, Joaquin Portilla,
More informationRajesh T. Gandhi, M.D.
HIV Treatment Guidelines: 2010 Rajesh T. Gandhi, M.D. Case 29 yo M with 8 weeks of cough and fever. Diagnosed with smear-positive pulmonary TB. HIV-1 antibody positive. CD4 count 361. HIV-1 RNA 23,000
More informationMDR HIV and Total Therapeutic Failure. Douglas G. Fish, MD Albany Medical College Albany, New York Cali, Colombia March 30, 2007
MDR HIV and Total Therapeutic Failure Douglas G. Fish, MD Albany Medical College Albany, New York Cali, Colombia March 30, 2007 Objectives Case study Definitions Fitness Pathogenesis of resistant virus
More informationDidactic Series. Archive Genotype Resistance Testing in the Setting of Regimen Switching
Didactic Series Archive Genotype Resistance Testing in the Setting of Regimen Switching Craig Ballard, Pharm.D., AAHIVP UCSD Medical Center Owen Clinic June 11, 2015 ACCREDITATION STATEMENT: University
More informationResistance Characteristics of Integrase Inhibitors
Resistance Characteristics of Integrase Inhibitors Madrid, November 2016 Jonathan M Schapiro, MD National Hemophilia Center, Israel Stanford University School of Medicine, USA Disclaimer Presentation includes
More informationOptimizing 2 nd and 3 rd Line Antiretroviral Therapy in Children and Adolescents
Optimizing 2 nd and 3 rd Line Antiretroviral Therapy in Children and Adolescents Victor Musiime, MBChB, MMED, PhD Senior Lecturer, Makerere University Investigator, Joint Clinical Research Centre (JCRC)
More informationNew HIV EACS and Italian Guidelines
Original Article HIV correlated pathologies and other infections Marco Borderi New HIV EACS and Italian Guidelines Infectious Disease Unit - S. Orsola-Hospital - University of Bologna Corresponding author:
More informationACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals
ACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals ACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals Are You Ready? New Drugs Are on the Way!
More informationHIV Update. On The Cutting Edge A Chronic Disease. Rhett M Shirley, MD
HIV Update On The Cutting Edge A Chronic Disease Rhett M Shirley, MD CDC Mid-point life expectancy estimates at age 20 years in three calendar periods, overall and by sociodemographic characteristics,
More informationThe Dawn of the TLD Era
The Dawn of the TLD Era 20th September 2018 Mark Siedner Africa Health Research Institute Harvard Medical School Outline: A Primer on Dolutegravir Do we really need more HIV drugs? The case for a new first-line
More informationReal Life Experience of Dolutegravir and Lamivudine Dual Therapy As a Switching Regimen in HIVTR Cohort
Real Life Experience of Dolutegravir and Lamivudine Dual Therapy As a Switching Regimen in HIVTR Cohort Yagci-Caglayik D 1, Gokengin D 2, Inan A 3, Ozkan-Ozdemir H 4, Inan D 5, Akbulut A 6, Korten V 1,
More information